AIM AIM ImmunoTech
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
May 5, 2021
AIM IMMUNOTECH INC.
(Exact name of registrant as specified in its charter)
|Delaware||001 - 27072||52-0845822|
|(state or other jurisdiction||(Commission||(I.R.S. Employer|
|of incorporation)||File Number)||Identification No.)|
|2117 SW Highway 484, Ocala FL||34473|
|(Address of principal executive offices)||(Zip Code)|
Registrant’s telephone number, including area code: (352) 448-7797
AIM ImmunoTech Inc.
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|[ ]||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|[ ]||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company [ ]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Securities registered pursuant to Section 12(b) of the Act:
|Title of each class||Trading Symbol||Name of each exchange on which registered|
|Common Stock, par value $0.001 per share||AIM||NYSE American|
Item 8.01 Other Events.
On May 5, 2021, AIM ImmunoTech Inc. (the “Company”) filed one U.S. Provisional Patent Application for the Company’s drug Ampligen as a potential therapeutic to possibly slow, halt, or reverse the progression of Alzheimer’s disease.
No assurance can be given that this patent application or subsequent patent applications claiming priority to this application ultimately will be granted. In addition, whether or not Ampligen will be accepted as an approved therapeutic to slow, halt or reverse the progression of Alzheimer’s disease, will require significant testing, clinical trials, and regulatory approval. The Company cannot assure that any such trials will be successful, yield favorable data or not require additional funding. Clinical trials are subject to many factors including lack of regulatory approval(s), lack of study drug, or a change in priorities at the institutions sponsoring other trials.
|AIM IMMUNOTECH INC.|
|May 6, 2021||By:||/s/ Thomas K. Equels|
|Thomas K. Equels, CEO|